Cargando…

Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda

BACKGROUND: With the scale-up of antiretroviral therapy (ART), monitoring programme performance is needed to maximize ART efficacy and limit HIV drug resistance (HIVDR). METHODS: We implemented a WHO HIVDR prospective survey protocol at three treatment centers between 2012 and 2013. Data were abstra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaleebu, Pontiano, Kirungi, Wilford, Watera, Christine, Asio, Juliet, Lyagoba, Fred, Lutalo, Tom, Kapaata, Anne A., Nanyonga, Faith, Parry, Chris M., Magambo, Brian, Nazziwa, Jamirah, Nannyonjo, Maria, Hughes, Peter, Hladik, Wolfgang, Ruberantwari, Anthony, Namuwenge, Norah, Musinguzi, Joshua, Downing, Robert, Katongole-Mbidde, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689474/
https://www.ncbi.nlm.nih.gov/pubmed/26700639
http://dx.doi.org/10.1371/journal.pone.0145536
_version_ 1782406850102165504
author Kaleebu, Pontiano
Kirungi, Wilford
Watera, Christine
Asio, Juliet
Lyagoba, Fred
Lutalo, Tom
Kapaata, Anne A.
Nanyonga, Faith
Parry, Chris M.
Magambo, Brian
Nazziwa, Jamirah
Nannyonjo, Maria
Hughes, Peter
Hladik, Wolfgang
Ruberantwari, Anthony
Namuwenge, Norah
Musinguzi, Joshua
Downing, Robert
Katongole-Mbidde, Edward
author_facet Kaleebu, Pontiano
Kirungi, Wilford
Watera, Christine
Asio, Juliet
Lyagoba, Fred
Lutalo, Tom
Kapaata, Anne A.
Nanyonga, Faith
Parry, Chris M.
Magambo, Brian
Nazziwa, Jamirah
Nannyonjo, Maria
Hughes, Peter
Hladik, Wolfgang
Ruberantwari, Anthony
Namuwenge, Norah
Musinguzi, Joshua
Downing, Robert
Katongole-Mbidde, Edward
author_sort Kaleebu, Pontiano
collection PubMed
description BACKGROUND: With the scale-up of antiretroviral therapy (ART), monitoring programme performance is needed to maximize ART efficacy and limit HIV drug resistance (HIVDR). METHODS: We implemented a WHO HIVDR prospective survey protocol at three treatment centers between 2012 and 2013. Data were abstracted from patient records at ART start (T1) and after 12 months (T2). Genotyping was performed in the HIV pol region at the two time points. RESULTS: Of the 425 patients enrolled, at T2, 20 (4.7%) had died, 66 (15.5%) were lost to follow-up, 313 (73.6%) were still on first-line, 8 (1.9%) had switched to second-line, 17 (4.0%) had transferred out and 1 (0.2%) had stopped treatment. At T2, 272 out of 321 on first and second line (84.7%) suppressed below 1000 copies/ml and the HIV DR prevention rate was 70.1%, just within the WHO threshold of ≥70%. The proportion of participants with potential HIVDR was 20.9%, which is higher than the 18.8% based on pooled analyses from African studies. Of the 35 patients with mutations at T2, 80% had M184V/I, 65.7% Y181C, and 48.6% (54.8% excluding those not on Tenofovir) had K65R mutations. 22.9% had Thymidine Analogue Mutations (TAMs). Factors significantly associated with HIVDR prevention at T2 were: baseline viral load (VL) <100,000 copies/ml [Adjusted odds ratio (AOR) 3.13, 95% confidence interval (CI): 1.36–7.19] and facility. Independent baseline predictors for HIVDR mutations at T2 were: CD4 count <250 cells/μl (AOR 2.80, 95% CI: 1.08–7.29) and viral load ≥100,000 copies/ml (AOR 2.48, 95% CI: 1.00–6.14). CONCLUSION: Strengthening defaulter tracing, intensified follow-up for patients with low CD4 counts and/or high VL at ART initiation together with early treatment initiation above 250 CD4 cells/ul and adequate patient counselling would improve ART efficacy and HIVDR prevention. The high rate of K65R and TAMs could compromise second line regimens including NRTIs.
format Online
Article
Text
id pubmed-4689474
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-46894742015-12-31 Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda Kaleebu, Pontiano Kirungi, Wilford Watera, Christine Asio, Juliet Lyagoba, Fred Lutalo, Tom Kapaata, Anne A. Nanyonga, Faith Parry, Chris M. Magambo, Brian Nazziwa, Jamirah Nannyonjo, Maria Hughes, Peter Hladik, Wolfgang Ruberantwari, Anthony Namuwenge, Norah Musinguzi, Joshua Downing, Robert Katongole-Mbidde, Edward PLoS One Research Article BACKGROUND: With the scale-up of antiretroviral therapy (ART), monitoring programme performance is needed to maximize ART efficacy and limit HIV drug resistance (HIVDR). METHODS: We implemented a WHO HIVDR prospective survey protocol at three treatment centers between 2012 and 2013. Data were abstracted from patient records at ART start (T1) and after 12 months (T2). Genotyping was performed in the HIV pol region at the two time points. RESULTS: Of the 425 patients enrolled, at T2, 20 (4.7%) had died, 66 (15.5%) were lost to follow-up, 313 (73.6%) were still on first-line, 8 (1.9%) had switched to second-line, 17 (4.0%) had transferred out and 1 (0.2%) had stopped treatment. At T2, 272 out of 321 on first and second line (84.7%) suppressed below 1000 copies/ml and the HIV DR prevention rate was 70.1%, just within the WHO threshold of ≥70%. The proportion of participants with potential HIVDR was 20.9%, which is higher than the 18.8% based on pooled analyses from African studies. Of the 35 patients with mutations at T2, 80% had M184V/I, 65.7% Y181C, and 48.6% (54.8% excluding those not on Tenofovir) had K65R mutations. 22.9% had Thymidine Analogue Mutations (TAMs). Factors significantly associated with HIVDR prevention at T2 were: baseline viral load (VL) <100,000 copies/ml [Adjusted odds ratio (AOR) 3.13, 95% confidence interval (CI): 1.36–7.19] and facility. Independent baseline predictors for HIVDR mutations at T2 were: CD4 count <250 cells/μl (AOR 2.80, 95% CI: 1.08–7.29) and viral load ≥100,000 copies/ml (AOR 2.48, 95% CI: 1.00–6.14). CONCLUSION: Strengthening defaulter tracing, intensified follow-up for patients with low CD4 counts and/or high VL at ART initiation together with early treatment initiation above 250 CD4 cells/ul and adequate patient counselling would improve ART efficacy and HIVDR prevention. The high rate of K65R and TAMs could compromise second line regimens including NRTIs. Public Library of Science 2015-12-23 /pmc/articles/PMC4689474/ /pubmed/26700639 http://dx.doi.org/10.1371/journal.pone.0145536 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Kaleebu, Pontiano
Kirungi, Wilford
Watera, Christine
Asio, Juliet
Lyagoba, Fred
Lutalo, Tom
Kapaata, Anne A.
Nanyonga, Faith
Parry, Chris M.
Magambo, Brian
Nazziwa, Jamirah
Nannyonjo, Maria
Hughes, Peter
Hladik, Wolfgang
Ruberantwari, Anthony
Namuwenge, Norah
Musinguzi, Joshua
Downing, Robert
Katongole-Mbidde, Edward
Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda
title Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda
title_full Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda
title_fullStr Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda
title_full_unstemmed Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda
title_short Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda
title_sort virological response and antiretroviral drug resistance emerging during antiretroviral therapy at three treatment centers in uganda
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689474/
https://www.ncbi.nlm.nih.gov/pubmed/26700639
http://dx.doi.org/10.1371/journal.pone.0145536
work_keys_str_mv AT kaleebupontiano virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT kirungiwilford virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT waterachristine virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT asiojuliet virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT lyagobafred virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT lutalotom virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT kapaataannea virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT nanyongafaith virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT parrychrism virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT magambobrian virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT nazziwajamirah virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT nannyonjomaria virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT hughespeter virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT hladikwolfgang virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT ruberantwarianthony virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT namuwengenorah virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT musinguzijoshua virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT downingrobert virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT katongolembiddeedward virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda
AT virologicalresponseandantiretroviraldrugresistanceemergingduringantiretroviraltherapyatthreetreatmentcentersinuganda